This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-22. Anything still debated is marked as such rather than presented as settled.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Edith died on 29 November 1971, at the age of 82. Ronald returned to Oxford, where Merton College gave him convenient rooms near the High Street. He missed Edith, but enjoyed being back in the city. Tolkien was made a Commander of the Order of the British Empire in the 1972 New Year Honours and received the insignia of the Order at Buckingham Palace on 28 March 1972. In the same year Oxford University gave him an honorary Doctorate of Letters. He was further awarded an honorary Doctorate of Letters from the University of Edinburgh on 22 July 1973. He had the name Luthien [sic] engraved on Edith's tombstone at Wolvercote Cemetery, Oxford. When Tolkien died 21 months later on 2 September 1973 from a bleeding ulcer and chest infection, at the age of 81, he was buried in the same grave, with "Beren" added to his name. Tolkien's will was proven on 20 December 1973, with his estate valued at £190,577 (equivalent to £2,991,790 in 2026).
After the collapse of the Soviet Union, there were 910 higher educational institutions on the territory of Ukraine, and over the years there has been a tendency to reduce their number. Despite the decline of universities, the number of university students increased from 881,000 in 1990/1991 to 2.4 million in 2007/2008. Taras Shevchenko National University of Kyiv, founded in 1834 and located in Kyiv, is one of the most prestigious universities in Ukraine. National University of Kharkiv was founded in 1804 in Kharkiv and since then has become one of the largest universities in Eastern Europe.
Organic cofactors, such as ATP and NADH, are present in all known forms of life and form a core part of metabolism. Such universal conservation indicates that these molecules evolved very early in the development of living things. At least some of the current set of cofactors may, therefore, have been present in the last universal ancestor, which lived about 4 billion years ago. Organic cofactors may have been present even earlier in the history of life on Earth. The nucleotide adenosine is a cofactor for many basic metabolic enzymes such as transferases. It may be a remnant of the RNA world. Adenosine-based cofactors may have acted as adaptors that allowed enzymes and ribozymes to bind new cofactors through small modifications in existing adenosine-binding domains, which had originally evolved to bind a different cofactor. This process of adapting a pre-evolved structure for a novel use is known as exaptation. Prebiotic origin of coenzymes. Like amino acids and nucleotides, certain vitamins and thus coenzymes can be created under early earth conditions. For instance, vitamin B3 can be synthesized with electric discharges applied to ethylene and ammonia. Similarly, pantetheine (a vitamin B5 derivative), a precursor of coenzyme A and thioester-dependent synthesis, can be formed spontaneously under evaporative conditions. Other coenzymes may have existed early on Earth, such as pterins (a derivative of vitamin B9), flavins (FAD, flavin mononucleotide = FMN), and riboflavin (vitamin B2). Changes in coenzymes.
=== Hyperthermia therapy === Hyperthermia therapy is heat treatment for cancer that can be a powerful tool when used in combination with chemotherapy (thermochemotherapy) or radiation for the control of a variety of cancers. The heat can be applied locally to the tumor site, which will dilate blood vessels to the tumor, allowing more chemotherapeutic medication to enter the tumor. Additionally, the tumor cell membrane will become more porous, further allowing more of the chemotherapeutic medicine to enter the tumor cell. Hyperthermia has also been shown to help prevent or reverse "chemo-resistance." Chemotherapy resistance sometimes develops over time as the tumors adapt and can overcome the toxicity of the chemo medication. "Overcoming chemoresistance has been extensively studied within the past, especially using CDDP-resistant cells. In regard to the potential benefit that drug-resistant cells can be recruited for effective therapy by combining chemotherapy with hyperthermia, it was important to show that chemoresistance against several anticancer drugs (e.g. mitomycin C, anthracyclines, BCNU, melphalan) including CDDP could be reversed at least partially by the addition of heat.
Use of DART compared to traditional methods minimizes sample amount, sample preparation, eliminates extraction steps, decreases limit of detection and analysis time. Also it provides a broad range sensitivity, simultaneous determination of multi-drug analytes and sufficient mass accuracy for formulation determination. The DART ion source is a kind of gas-phase ionization, and it requires some sort of volatility of the analyte to support thermally assisted desorption of analyte ions. This limits the size range of the molecules that can be analyzed by DART i.e. m/z 50 to 1200. DART-MS is capable of semi-quantitative and quantitative analysis. To accelerate sample release from the surface, the DART gas stream is usually heated to temperature in the range 100-500 °C and this operation can be employed for temperature-dependent analysis.
Sources: en.wikipedia.org
=== Others === TCI Transportation Company Nigeria Limited,TCI Global (HKG) Limited, TCI Chatbot, TCI Global Logistik Verwaltungs GmbH i.L. Eschborn, TCI Global (Thailand) Co., Ltd., TCI Global (Malaysia) SDN. BHD., TCI Holdings SA&E Pte Ltd, TCI Global Brazil Logistica Ltda, TCI Global Holdings (Mauritius) Limited, TCI Global (Singapore) Pte Ltd, TCI Crystal Report, TCI Holdings Asia Pacific Pte Ltd, TCI Global Shanghai Company Limited,PT TCI Global Indonesia,TCI Prosperities Pune Ltd
=== Food waste reduction === Approximately one-third of all food produced globally is wasted. Innovative food tech solutions are being developed to address this issue. For example, Apeel Sciences has developed an edible coating that extends the shelf life of fruits and vegetables, reducing spoilage and waste.
== Adverse effects == Although ayahuasca is generally safe in traditional use, adverse effects can occur. In the short term, ingesting ayahuasca can cause nausea, vomiting, and diarrhea. These three effects, known as purging, are traditionally recognized to be a part of the spiritual experience of ayahuasca. Physiologically, vomiting may be related to increased serotonergic signaling in the gut, which directly stimulates the vagus nerve. Other short-term side effects include increased blood pressure and tachycardia. Additionally, increased secretion of hormones like prolactin, cortisone, and growth hormone has been correlated with ayahuasca consumption. Rarer side effects include shortness of breath, seizures and serotonin syndrome. Ayahuasca is suspected of triggering psychosis and schizophrenia in people with a predisposition to the condition, and there is a lack of safety information for ayahuasca's possible effects on pregnancy and breastfeeding. A 2024 review found that traditional ayahuasca use is generally safe, but higher doses of ayahuasca or higher doses of isolated harmala alkaloids like harmaline may pose risks.
=== Deficiency === Diminished secretion of LH can result in failure of gonadal function (hypogonadism). This condition is typically manifest in males as failure in production of normal numbers of sperm. In females, amenorrhea is commonly observed. Conditions with very low LH secretions include:
In Hinduism, the Upanishads say that the nature of the higher self (Brahman), in essence, is bliss (ānanda), which the self in each being (Atman) experiences during dreamless deep sleep but remains unconscious of, consciously experiencing it during sensual activity. The Upanishads say that in humans, just as eyes correspond to the experience of sight, nose with smell, ears with sound, and tongue with taste, the genitals correspond to "bliss, delight and procreation". The Brihadaranyaka Upanishad says that in humans, genitals are the "single locus of pleasure (ānanda)". In Sanskrit literature, the penis is called Upastha ("that which stands up") and is traditionally considered a "source of great power or vitality (ojas)." In Yoga physiology, the penis corresponds with svadhishthana chakra, and channels the flow of nadis, which enable higher sensations and consciousness. Consequently, circumcision, or even an interference with a tight foreskin, is strictly forbidden in Hindu traditions.
Sources: en.wikipedia.org
traffic in refrigerated fruit hit 600,000 short tons (544,311 t; 535,714 long tons). 1908: Japan's first refrigerator cars entered service. The cars were used for seafood transport, as with most other Japanese reefers. 1913: The number of thermally insulated railcars (most of which were cooled by ice) in the U.S. topped 100,000. 1920: The Fruit Growers Express (or FGE, a former subsidiary of the Armour Refrigerator Line) was formed using 4,280 reefers acquired from Armour & Co. 1923: FGE and the Great Northern Railway form the Western Fruit Express (WFE) to compete with the Pacific Fruit Express and Santa Fe Refrigerator Despatch in the West. 1925 to 1930: Mechanically refrigerated trucks enter service and gain public acceptance, particularly for the delivery of milk and ice cream. 1926: The FGE expanded its service into the Pacific Northwest and the Midwest through the WFE and the Burlington Refrigerator Express Company (BREX), its other partly owned subsidiary. FGE purchased 2,676 reefers from the Pennsylvania Railroad. 1928: The FGE formed the National Car Company as a subsidiary to service the meat transportation market. Customers include Kahns, Oscar Mayer, and Rath. 1930: The number of refrigerator cars in the United States reached its maximum of approximately 183,000. 1931: The SFRD reconfigured seven reefers to use dry ice as a cooling agent. 1932: Japanese Government Railways built vehicles specially made for dry ice coolant. 1934: The Interstate Commerce Commission (ICC) regulation #201 came into effect, banning billboard advertisements on freight cars.
A rapidly increasing list of production techniques have been developed to enable graphene's use in commercial applications. Isolated 2D crystals cannot be grown via chemical synthesis beyond small sizes even in principle, because the rapid growth of phonon density with increasing lateral size forces 2D crystallites to bend into the third dimension. In all cases, graphene must bond to a substrate to retain its two-dimensional shape.
x = number of abnormal spermatozoa. h = number of spermatozoa with head abnormalities. m = number of spermatozoa with midpiece abnormalities. t = number of spermatozoa with tail abnormalities. Another interesting index is the sperm deformity index (SDI), which is calculated the same way as the TZI, but instead of dividing by the number of abnormal spermatozoa, the division is by the total number of spermatozoa counted. The TZI takes values from 1 (only one abnormality per sperm) to 3 (each sperm has the three types of abnormalities). Morphology is a predictor of success in fertilizing oocytes during in vitro fertilization. Up to 10% of all spermatozoa have observable defects and as such are disadvantaged in terms of fertilising an oocyte. Also, sperm cells with tail-tip swelling patterns generally have lower frequency of aneuploidy.
After the completion of the coupling reaction, a small percentage of the solid support-bound 5'-OH groups (0.1 to 1%) remains unreacted and needs to be permanently blocked from further chain elongation to prevent the formation of oligonucleotides with an internal base deletion commonly referred to as (n-1) shortmers. The unreacted 5'-hydroxy groups are, to a large extent, acetylated by the capping mixture. It has also been reported that phosphoramidites activated with 1H-tetrazole react, to a small extent, with the O6 position of guanosine. Upon oxidation with I2 /water, this side product, possibly via O6-N7 migration, undergoes depurination. The apurinic sites thus formed are readily cleaved in the course of the final deprotection of the oligonucleotide under the basic conditions (see below) to give two shorter oligonucleotides thus reducing the yield of the full-length product. The O6 modifications are rapidly removed by treatment with the capping reagent as long as the capping step is performed prior to oxidation with I2/water. The synthesis of oligonucleotide phosphorothioates (OPS, see below) does not involve the oxidation with I2/water, and, respectively, does not suffer from the side reaction described above. On the other hand, if the capping step is performed prior to sulfurization, the solid support may contain the residual acetic anhydride and N-methylimidazole left after the capping step.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.